{
    "clinical_study": {
        "@rank": "142973", 
        "arm_group": [
            {
                "arm_group_label": "surgery", 
                "arm_group_type": "Active Comparator", 
                "description": "The control group of the study is comprised of patients that will undergo the current standard surgical treatment of papillary thyroid carcinoma:  total thyroidectomy by one of the high-volume endocrine surgeons at Yale Endocrine Surgery."
            }, 
            {
                "arm_group_label": "percutaneous ethanol ablation", 
                "arm_group_type": "Experimental", 
                "description": "The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma."
            }
        ], 
        "brief_summary": {
            "textblock": "We will compare the effectiveness of surgery and percutaneous ethanol ablation for the\n      treatment of thyroid cancer."
        }, 
        "brief_title": "Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Papillary Thyroid Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "We hypothesize that percutaneous ethanol ablation for primary papillary thyroid\n      microcarcinoma has equivalent oncologic outcomes to current treatment options including\n      observation, thyroid lobectomy and total thyroidectomy.  In addition, we hypothesize that it\n      will yield superior long-term quality of life, including measures of pain, voice, and\n      cosmesis than standard surgical therapy (total thyroidectomy).  If our hypotheses are\n      correct, the findings of this study have the potential to fundamentally change clinical\n      management of this group of patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years and older\n\n          -  Diagnosis:  single, cytology-proven papillary thyroid carcinoma measuring 1 cm or\n             less in diameter (microcarcinoma, T1a), without visible extrathyroidal extension, and\n             with negative central and lateral neck lymph nodes by ultrasound\n\n        Exclusion Criteria:\n\n          -  Patient refusal to participate\n\n          -  History of prior thyroid or parathyroid surgery\n\n          -  Previous recurrent laryngeal nerve injury\n\n          -  Inability to make decisions or comply with follow up\n\n          -  Co-existing indication for thyroidectomy\n\n          -  Aggressive cytological or molecular features\n\n          -  Multifocal papillary thyroid carcinoma\n\n          -  Pregnant or breast-feeding\n\n          -  Anatomically unfavorable location of the tumor (proximity to recurrent laryngeal\n             nerve or trachea)\n\n          -  Documented or suspected distant metastasis\n\n          -  History of radiation to neck or face\n\n          -  Family history of thyroid cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974284", 
            "org_study_id": "HIC1312013168"
        }, 
        "intervention": [
            {
                "arm_group_label": "percutaneous ethanol ablation", 
                "description": "The volume of 99% ethanol to be injected is calculated using a standardized formula.  Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.", 
                "intervention_name": "percutaneous ethanol ablation", 
                "intervention_type": "Drug", 
                "other_name": [
                    "percutaneous", 
                    "ethanol", 
                    "ablation", 
                    "papillary", 
                    "thyroid", 
                    "microcarcinoma", 
                    "PTMC"
                ]
            }, 
            {
                "arm_group_label": "surgery", 
                "description": "A total thyroidectomy is the current standard of care at our institution for patients with papillary thyroid microcarcinoma.", 
                "intervention_name": "Total thyroidectomy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ethanol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "contact": {
                "email": "amir.lebastchi@yale.edu", 
                "last_name": "Amir Lebastchi, MD", 
                "phone": "203-785-3767"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06520"
                }, 
                "name": "Endocrine Surgery Smilow Cancer Hospital at Yale-New Haven"
            }, 
            "investigator": {
                "last_name": "Glenda Callender, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma", 
        "overall_official": {
            "affiliation": "Yale University- Department of Surgery", 
            "last_name": "Glenda Callender, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary endpoint of the study consists of the oncological outcome, which includes the disease-free status of the patients. We will compare the disease-free and overall survival of the patients between the two treatment arms and hope to find a clinically-significant difference.", 
                "measure": "Disease-free", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Primary endpoint of the study consists of the oncological outcome, which includes the overall survival of the patients. We will compare the disease-free and overall survival of the patients between the two treatment arms and hope to find a clinically-significant difference.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Short-Form-36 (SF-36) health survey is a patient-reported survery that evaluates the patient's health status.  It consists of 8 scaled scores which are the weighted sums of the questions in each section.  The 8 sections that are tested are vitality, physical functioning, bodily pain, general role functioning, emotional role functioning, social role functioning, and mental health.  Each scale is directly transformed into a 0-100 scale; the higher the score, the less disability (i.e. the score of 0 is equivalent to maximal disability, and the score of 100 is equivalent of no disability).  The SF-36 is a set of easily-administered quality-of-life measures and is a validated tool to evaluate patient quality of life.", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Patient satisfaction will be assessed by evaluating the following:  pain with the \"Brief Pain Inventory\" (BPI), voice with the \"Voice Handicap Index\" (VHI) and cosmesis with the \"Patient and Observer Scar Assessment Scale\" (POSAS).  The BPI is a simple, well-accepted instrument for the objective assessment of pain.  The VHI is an established tool used to assess voice after an intervention.  POSAS is a validated tool for the evaluation of surgical scars.", 
                "measure": "Patient Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}